DOI: 10.36347/sjams.2024.v12i05.029

Pages: 689-693

Background: Androgenic alopecia (AGA) is a prevalent form of hair loss affecting millions worldwide, primarily influenced by genetic and hormonal factors. Platelet-Rich Plasma (PRP) injections have emerged as a promising therapeutic avenue for AGA treatment, offering hope to those facing hair loss. Objective: This study aimed to evaluate the effectiveness of PRP injections in treating AGA in both men and women. Methods: A prospective observational study was conducted at a tertiary hospital from June 2022 to June 2023. 30 patients with mild to moderate AGA were selected. PRP therapy was administered over three months, with regular assessments. Scalp examinations were conducted, and a control group received medical treatment without PRP. Contraindications for PRP therapy were noted. Results: The study group predominantly consists of individuals aged 25 to 40 years old, with 66.67% falling within the 25-34 age bracket and the remaining 33.33% in the 35-40 age group. Additionally, the incidence of hair fall is notably higher in males, comprising 96% of the total patients. Observations on the hair pull test before and after 12 weeks of Platelet-Rich Plasma (PRP) therapy for androgenic alopecia demonstrate a significant improvement in hair retention, with reductions in hair loss across all categories. Notably, 80% of participants observed new hair growth within just one week post-treatment, while the remaining 20% reported new hair growth taking longer than a week to become apparent. Conclusion: PRP injection presents a simple, cost-effective, and viable solution for AGA treatment. While further research is warranted to validate its efficacy, PRP therapy holds potential as a hopeful option for individuals experiencing hair loss.